To investigate mechanisms underlying accelerated carcinogenesis in mice carrying a human prototype c-Ha- ras gene (rasH2 mouse), mutations and the expression profile of the transgene were evaluated in 14 tumors induced by a single injection of ethylnitrosourea (ENU), with or without additional beta-estradiol 3-benzoate (EB) treatment. Although no codon 12 mutations were detected, changes in codon 61 were evident in all lung adenocarcinomas, skin squamous cell carcinomas and forestomach squamous cell carcinomas examined. The mRNA levels of the transgene in these lesions were also elevated 1.71- to 4.77-fold, 3.04- to 5.18-fold, and 3.00- to 5.67-fold, respectively, in comparison with those in the normal livers of rasH2 mice. The results obtained in this study suggest that mutations in codon 61 and amplification of the transgene play key roles in the carcinogenesis induced by ENU in rasH2 mice.
Anderson D. -2001-. Expression of ras -p21- protein in plasma from exposed workers and from patients with lung disease. Int J Hyg EnvironHealth204: 55—60.
2.
Ando K., Saitoh A., Hino O., Takahashi R., Kimura M., Katsuki M. -1992-. Chemically induced forestomach papillomas in transgenic mice carry mutant human c-Ha-ras transgenes. Cancer Res52: 978—982.
3.
Biankin AV, Kench JG, Morey AL, Lee CS, Biankin SA, Head DR, Hugh TB, Henshall SM, Sutherland RL -2001-. Overexpression of p21-WAF1/CIP1- is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res61: 8830—8837.
4.
Coutinho CM, Bassini AS, Gutierrez LG, Butugan O., Kowalski LP, Brentani MM, Nagai MA -1999-. Genetic alterations in Ki-ras and Ha-ras genes in juvenile nasopharyngeal angiofibromas and head and neck cancer. Sao PauloMed J117: 113—120.
5.
Gulezian D., Jacobson-Kram D., McCullough CB, Olson H., Recio L., Robinson D., Storer R., Tennant R., Ward JM, Neumann DA -2000-. Use of transgenic animals for carcinogenicity testing: Considerations and implications for risk assessment. Toxicol Pathol28: 482—499.
6.
Hayashi S., Mori I., Nonoyama T., Mitsumori K. -1998-. Point mutations of the c-Ha-ras gene in spontaneous liver tumors of transgenic mice carrying the human c-Ha-ras gene. Toxicol Pathol26: 556—561.
7.
Koujitani T. , Yasuhara K., Usui T., Nomura T., Onodera H., Takagi H., Hirose M., Mitsumori K. -2000-. Lack of susceptibility of transgenic mice carrying the human c-Ha-ras proto-oncogene -rasH2 mice- to phenolphthalein in a 6-month carcinogenicity study. Cancer Lett152: 211—216.
8.
Liu ML, Von Lintig FC, Liyanage M., Shibata MA, Jorcyk CL, Ried T., Boss GR, Green JE -1998-. Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3-1-/SV40 Tag transgenic mice . Oncogene18: 2403—2411.
9.
Maronpot RR, Mitsumori K., Mann P., Takaoka M., Yamamoto S., Usui T., Okamiya H., Nishikawa S., Nomura T. -2000-. Interlaboratory comparison of the CB6F1-Tg rasH2 rapid carcinogenicity testing model. Toxicology146: 149—159.
10.
Maruyama C. , Tomisawa M., Wakana S., Yamazaki H., Kijima H., Suemizu H., Ohnishi Y., Urano K., Hioki K., Usui T., Nakamura M., Tsuchida T., Mitsumori K., Nomura T., Tamaoki N., Ueyama Y. -2001-. Overexpression of human H-ras transgene is responsible for tumors induced by chemical carcinogens in mice. Oncol Rep8: 233—237.
11.
Mitsumori K. , Furukawa F., Sato M., Yoshimura H., Imazawa T., Nishikawa A., Takahashi M. -1994-. Promoting effects of ethinyl estradiol on development of renal proliferative lesions induced by N-nitrosobis -2-oxopropyl-amine in female Syrian golden hamsters. J Cancer Res Clin Oncol120: 131—136.
12.
Mitsumori K. , Wakana S., Yamamoto S., Kodama Y., Yasuhara K., Nomura T., Hayashi Y., Maronpot RR -1997-. Susceptibility of transgenic mice carrying human prototype c-Ha-ras gene in a short-term carcinogenicity study of vinyl carbamate and ras gene analyses of the induced tumors. Mol Carcinog20: 298—307.
13.
Mitsumori K. , Koizumi H., Nomura T., Yamamoto S. -1998-. Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies. Toxicol Pathol26: 520—531.
14.
Mori I., Yasuhara K., Hayashi S., Nonoyama T., Nomura T., Mitsumori K. -2000-. Carcinogen dose-dependent variation in the transgene mutation spectrum in urethane-induced lung tumors in transgenic mice carrying the human prototype c-Ha-ras gene. Cancer Lett153: 199—209.
15.
Mori I., Hayashi S., Nonoyama T., Yasuhara K., Mitsumori K., Masegi T. -2000-. Point mutations of the c-Ha-ras gene in spontaneous pulmonary tumors of transgenic mice carrying the human c-Ha-ras gene. J Toxicol Pathol13: 165—172.
16.
Ogasawara H. , Tsutsumi M., Takeda K., Usui K., Kobayashi H., Murakami H., Takagi H., Kumagai T., Konishi Y. -2000-. Utility of transgenic mice carrying human prototype c-Ha-ras gene for alternative carcinogenicity testing of chemicals-negative results with Methapyrilene hydrochloride. J Toxicol Pathol13: 179—188.
17.
Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A., Lynch HT, Smyrk TC -2002-. AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis23: 201—205.
18.
Saitoh A., Kimura M., Takahashi R., Yokoyama M., Nomura T., Izawa M., Sekiya T., Nishimura S., Katsuki M. -1990-. Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene5: 1195—1200.
19.
Storer RD -2000-. Current status and use of short/medium term models for carcinogenicity testing of pharmaceuticals—scientific perspective . Toxicol Lett112—113: 557—566.
20.
Solanas M., Escrich E. -1996-. Ha-ras in normal and tumoral tissues: Structure, function and regulation. Rev Esp Fisiol52: 173—192.
21.
Suemizu H., Muguruma K., Maruyama C., Tomisawa M., Kimura M., Hioki K., Shimozawa N., Ohnishi Y., Tamaoki N., Nomura T. -2002-. Transgene stability and features of rasH2 mice as an animal model for short-term carcinogenicity testing. MoleculCarcinogenesis34: 1—9.
22.
Sun XF, Ekberg H., Zhang H., Carstensen JM, Nordenskjold B. -1998-. Overexpression of ras is an independent prognostic factor in colorectal adenocarcinoma. APMIS106: 657—664.
23.
Tamaoki N. -2001-. The rasH2 transgenic mouse: Nature of the model and mechanistic studies on tumorigenesis. Toxicol Pathol29-suppl-: 81—89.
24.
Toyosawa K. , Okimoto K., Kobayashi I., Kijima K., Kikawa E., Kohchi M., Koujitani T., Tanaka K., Matsuoka N. -2001-. Di-2-ethylhexyl-phthalate induces hepatocellular adenoma in transgenic mice carrying a human prototype c-Ha-ras gene in a 26-week carcinogenicity study. Toxicol Pathol29: 458—466.
25.
Vickers AE, Lucier GW -1991-. Estrogen receptor, epidermal growth factor receptor and cellular ploidy in elutriated subpopulations of hepatocytes during liver tumor promotion by 17 alpha-ethinylestradiol in rats. Carcinogenesis12: 391—399.
26.
Yamamoto S. , Mitsumori K., Kodama Y., Matsunuma N., Manabe S., Okamiya H., Suzuki H., Fukuda T., Sakamaki Y., Sunaga M., Nomura G., Hioki K., Wakana S., Nomura T., Hayashi Y. -1996-. Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice. Carcinogenesis17: 2455—2461.
27.
Yamamoto S. , Hayashi Y., Mitsumori K., Nomura T. -1997-. Rapid carcinogenicity testing system with transgenic mice harboring human prototype c-HRAS gene . Lab Anim Sci47: 121—126.
28.
Yamamoto S. , Urano K., Koizumi H., Wakana S., Hioki K., Mitsumori K., Kurokawa Y., Hayashi Y., Nomura T. -1998-. Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Environ Health Perspect106-suppl. 1-: 57—69.
29.
Yamamoto S. , Urano K., Nomura T. -1998-. Validation of transgenic mice harboring the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. Toxicol Lett102—103: 473—478.
